The financing follows a strategic shift for Orum, which shelved its original lead program and is now pursuing a potential ...

Backed by a handful of prominent investors including the Gates Foundation, the startup is pursuing an approach it believes ...

The FDA contacted J&J right after ASH to discuss using a special fast pass on a multiple myeloma regimen. Elsewhere, a new ...

Despite being unable to declare statistical success, the company claimed its therapy showed enough promise to support moving ...

The approval could help Enhertu, which is already a multibillion-dollar seller, supplant a regimen that’s been the standard ...

The gene therapy developer has lost most of its value since going public in 2020 and saw a long road ahead for a delivery ...

The company will stop two trials testing its blockbuster therapy Vyvgart in thyroid eye disease after treatment was judged to ...

Tolebrutinib, which Sanofi acquired in a $3.7 billion buyout, failed a Phase 3 study in “primary progressive” multiple ...

The company intends to file a U.S. application in the first half of 2026 following positive study results in a condition ...

Discover why refining COAs is essential to capturing subtle, meaningful patient change—and how teams can close the ...

The deal revolves around a drug Sobi claimed could become the “therapy of choice” for people whose gout symptoms persist ...